(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

After approving Bavarian Nordic’s mpox vaccine in September for use in adults, the World Health Organisation has given the vaccine the green light for use in adolescents aged 12 to 17 years. It ...

GENEVA — The World Health Organization on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency's seal of approval. The ...

The World Health Organization Tuesday granted emergency use authorization for the second mpox vaccine. The LC16m8 vaccine from Japan's KM Biologics is the second since WHO declared mpox a health ...

WHO authorizes Bavarian Nordic vaccine for mpox, offering hope for countries battling the disease. Vaccine can be used off-label for children and immunocompromised individuals.

The World Health Organization has given its authorization to a first vaccine to protect against mpox, a decision announced in such haste Friday that it caught even the head of the company that ...

The World Health Organization (WHO) has announced the MVA-BN vaccine as the first vaccine against mpox to be added to its prequalification list.

The World Health Organization says it has granted its first authorization for use of a vaccine against mpox in adults, calling it an important step toward fighting against the disease in Africa ...

Bavarian Nordic receives WHO prequalification for IMVANEX as the first vaccine against mpox, accelerating access in African countries.

A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a ...